We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

UPST:NASDAQUpstart Holdings, Inc. Analysis

Data as of 2026-06-16 - not real-time

$32.24

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Upstart (UPST) is trading at $32.24, comfortably above its 20‑day ($30.99) and 50‑day ($30.74) simple moving averages but still well under the 200‑day average ($40.58), indicating a short‑term bullish bias within a longer‑term downtrend. The RSI sits at 54.6, suggesting neutral momentum, while the MACD remains bullish with a modest histogram (+0.07). Volatility is exceptionally high at 71.6% over the past 30 days and beta exceeds 2.8, underscoring pronounced price swings and market sensitivity. Fundamentally, revenue surged 44.6% YoY to $1.17 B with an impressive 82.7% gross margin, yet operating cash flow and free cash flow are negative, and the debt‑to‑equity ratio is a staggering 269, flagging balance‑sheet strain. Valuation metrics are mixed: the trailing P/E of 78.6 dwarfs the industry average of 17.1, but a forward P/E of 9.4 hints at substantial earnings upside. The stock faces acute legal headwinds, with multiple securities‑fraud class actions alleging AI model mis‑calibration and a sharp decline in conversion rates, adding regulatory and reputational risk.
Given the technical support around $26.77 and resistance near $34.69, the price is perched midway, offering limited upside unless the litigation resolves favorably and cash‑flow improvements materialize. The high growth profile and forward earnings potential support a longer‑term view, but the current overvaluation, debt burden, and extreme market sentiment (Fear & Greed Index at "Extreme Greed") suggest caution for near‑term investors.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Pending securities‑fraud class actions increasing legal uncertainty
  • High short‑term volatility and beta
  • Price near resistance with limited upside

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Strong revenue growth and high gross margins
  • Forward P/E compression suggesting earnings improvement
  • Ongoing legal resolution risk

Long Term

> 3 years
Positive
Model confidence: 6/10

Key Factors

  • AI‑driven lending platform with scalable growth potential
  • Undervalued forward earnings multiple
  • Potential balance‑sheet deleveraging if cash‑flow turns positive

Key Metrics & Analysis

Financial Health

Revenue Growth44.60%
Profit Margin4.21%
P/E Ratio78.6
ROE7.01%
ROA1.77%
Debt/Equity269.84
P/B Ratio4.2
Op. Cash Flow$-267536000
Free Cash Flow$-312582368
Industry P/E17.1

Technical Analysis

TrendNeutral
RSI54.6
Support$26.77
Resistance$34.69
MA 20$30.99
MA 50$30.74
MA 200$40.58
MACDBullish
VolumeStable
Fear & Greed Index92.13

Valuation

Target Price$40.13
Upside/Downside24.48%
GradeOvervalued
TypeBlend

Risk Assessment

Beta2.84
Volatility71.64%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.